Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
PHASE2
Neoadjuvant chemotherapy treatment can be used for specific UTUC patients, ...
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
PHASE3
The purpose of this study is to evaluate the efficacy and safety of \*\*Dis...
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
PHASE2
The efficacy and safety of combination with Disitamab Vedotin and with Tisl...
Status
Recruiting
Location
Tianjin Medical University Cancer Institute & Hospital